Journal for ImmunoTherapy of Cancer View Homepage


Ontology type: schema:Periodical      Open Access: True


Journal Info

START YEAR

2013

PUBLISHER

BioMed Central

LANGUAGE

en

HOMEPAGE

http://jitc.biomedcentral.com

Recent publications latest 20 shown

  • 2019-12 Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity.
  • 2019-12 Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition
  • 2019-12 Could the menagerie of the gut microbiome really cure cancer? Hope or hype
  • 2019-12 Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients
  • 2019-12 Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry
  • 2019-12 Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
  • 2019-12 Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial.
  • 2019-12 Immune-enrichment of non-small cell lung cancer baseline biopsies for multiplex profiling define prognostic immune checkpoint combinations for patient stratification
  • 2019-12 The IL-1/IL-1 receptor axis and tumor cell released inflammasome adaptor ASC are key regulators of TSLP secretion by cancer associated fibroblasts in pancreatic cancer
  • 2019-12 Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors
  • 2019-12 The immune suppressive microenvironment of human gliomas depends on the accumulation of bone marrow-derived macrophages in the center of the lesion
  • 2019-12 Combination treatment with hypofractionated radiotherapy plus IL-2/anti-IL-2 complexes and its theranostic evaluation
  • 2019-12 Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial
  • 2019-12 Nature of coexisting thyroid autoimmune disease determines success or failure of tumor immunity in thyroid cancer
  • 2019-12 EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy
  • 2019-12 Combined treatment with HMGN1 and anti-CD4 depleting antibody reverses T cell exhaustion and exerts robust anti-tumor effects in mice
  • 2019-12 Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?
  • 2019-12 Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma
  • 2019-12 Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitors
  • 2019-12 Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC)
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://scigraph.springernature.com/ontologies/product-market-codes/H33160", 
            "inDefinedTermSet": "http://scigraph.springernature.com/ontologies/product-market-codes/", 
            "name": "Oncology", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://scigraph.springernature.com/ontologies/product-market-codes/B14000", 
            "inDefinedTermSet": "http://scigraph.springernature.com/ontologies/product-market-codes/", 
            "name": "Immunology", 
            "type": "DefinedTerm"
          }
        ], 
        "contentRating": [
          {
            "author": "snip", 
            "ratingValue": "1.241", 
            "type": "Rating"
          }, 
          {
            "author": "sjr", 
            "ratingValue": "2.798", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2017", 
            "ratingValue": "8.374", 
            "type": "Rating"
          }
        ], 
        "description": "

    Journal for ImmunoTherapy of Cancer (JITC) is the premiere cancer immunotherapy journal at BMC, , and the official journal of the Society for Immunotherapy of Cancer (SITC). JITC welcomes basic, translational and clinical research and literature reviews on any aspect of tumor immunology and cancer immunotherapy. Topics of interest include tumor-host interactions, immune biomarkers, novel therapeutics, and immune-related toxicity.\u00a0 The journal\u2019s full collection, including its seminal guidelines and consensus statements, advances the rapidly evolving field of cancer immunotherapy through dissemination of rigorous peer-reviewed research.

    ", "editor": [ { "familyName": "Romero", "givenName": "Pedro", "type": "Person" } ], "id": "sg:journal.1049249", "inLanguage": [ "en" ], "isAccessibleForFree": true, "issn": [ "2051-1426" ], "license": "Fully Open Access", "name": "Journal for ImmunoTherapy of Cancer", "productId": [ { "name": "scopus_id", "type": "PropertyValue", "value": [ "21100466864" ] }, { "name": "wos_id", "type": "PropertyValue", "value": [ "2051-1426/JOURNAL FOR IMMUNOTHERAPY OF CANCER" ] }, { "name": "nlm_unique_id", "type": "PropertyValue", "value": [ "101620585" ] }, { "name": "springer_id", "type": "PropertyValue", "value": [ "40425" ] }, { "name": "lccn_id", "type": "PropertyValue", "value": [ "2013254548" ] }, { "name": "dimensions_id", "type": "PropertyValue", "value": [ "49249" ] } ], "publisher": { "name": "BioMed Central", "type": "Organization" }, "publisherImprint": "BioMed Central", "sameAs": [ "https://app.dimensions.ai/discover/publication?and_facet_source_title=jour.1049249" ], "sdDataset": "journals", "sdDatePublished": "2019-03-18T11:05", "sdLicense": "https://scigraph.springernature.com/explorer/license/", "sdPublisher": { "name": "Springer Nature - SN SciGraph project", "type": "Organization" }, "sdSource": "file:///home/ubuntu/piotr/scigraph_export/journals_20190313_sn_only.jsonl", "startYear": "2013", "type": "Periodical", "url": "http://jitc.biomedcentral.com" } ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/journal.1049249'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/journal.1049249'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/journal.1049249'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/journal.1049249'


     

    This table displays all metadata directly associated to this object as RDF triples.

    78 TRIPLES      21 PREDICATES      30 URIs      24 LITERALS      12 BLANK NODES

    Subject Predicate Object
    1 sg:journal.1049249 schema:about sg:ontologies/product-market-codes/B14000
    2 sg:ontologies/product-market-codes/H33160
    3 schema:contentRating N4d0f4db308524a11b1b5d3917145b2af
    4 Na59f1608968948ed800295b96775c643
    5 Nf5ae42558ee944f4b59314a643d0bddb
    6 schema:description <p><i>Journal for ImmunoTherapy of Cancer (JITC)</i> is the premiere cancer immunotherapy journal at BMC, , and the official journal of the Society for Immunotherapy of Cancer (SITC). JITC welcomes basic, translational and clinical research and literature reviews on any aspect of tumor immunology and cancer immunotherapy. Topics of interest include tumor-host interactions, immune biomarkers, novel therapeutics, and immune-related toxicity.  The journal’s full collection, including its seminal guidelines and consensus statements, advances the rapidly evolving field of cancer immunotherapy through dissemination of rigorous peer-reviewed research.</p>
    7 schema:editor N6e0fca28dccb4a4f9e087b2037e4feb0
    8 schema:inLanguage en
    9 schema:isAccessibleForFree true
    10 schema:issn 2051-1426
    11 schema:license Fully Open Access
    12 schema:name Journal for ImmunoTherapy of Cancer
    13 schema:productId N18819b809de54c54a4eed1b62a1b7570
    14 N1c1fdf3c321244e4a316bea598efd977
    15 N5242925a2b8842a2b3057b225febec97
    16 N93e93d28731e44f2a886817da031babe
    17 Na37661fe16cf401686b82db277cdf9bb
    18 Nc3a8c745133d47dd863e8b73a75ac2e4
    19 schema:publisher N7fcc2298ce8141de9f93552c05b6fdac
    20 schema:publisherImprint BioMed Central
    21 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_source_title=jour.1049249
    22 schema:sdDatePublished 2019-03-18T11:05
    23 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    24 schema:sdPublisher N5df892584b734a2897af6b8a68067b03
    25 schema:startYear 2013
    26 schema:url http://jitc.biomedcentral.com
    27 sgo:license sg:explorer/license/
    28 sgo:sdDataset journals
    29 rdf:type schema:Periodical
    30 N18819b809de54c54a4eed1b62a1b7570 schema:name dimensions_id
    31 schema:value 49249
    32 rdf:type schema:PropertyValue
    33 N1c1fdf3c321244e4a316bea598efd977 schema:name lccn_id
    34 schema:value 2013254548
    35 rdf:type schema:PropertyValue
    36 N4d0f4db308524a11b1b5d3917145b2af schema:author Nf055fbdbcbf74cd497adc7f8c110ea9c
    37 schema:ratingValue 1.241
    38 rdf:type schema:Rating
    39 N5242925a2b8842a2b3057b225febec97 schema:name springer_id
    40 schema:value 40425
    41 rdf:type schema:PropertyValue
    42 N5df892584b734a2897af6b8a68067b03 schema:name Springer Nature - SN SciGraph project
    43 rdf:type schema:Organization
    44 N6159a4958d00409494ebe4f342cc3653 rdf:first sjr
    45 rdf:rest rdf:nil
    46 N6dc234f78b124f1f9fc45fea0233737d schema:familyName Romero
    47 schema:givenName Pedro
    48 rdf:type schema:Person
    49 N6e0fca28dccb4a4f9e087b2037e4feb0 rdf:first N6dc234f78b124f1f9fc45fea0233737d
    50 rdf:rest rdf:nil
    51 N7fcc2298ce8141de9f93552c05b6fdac schema:name BioMed Central
    52 rdf:type schema:Organization
    53 N93e93d28731e44f2a886817da031babe schema:name scopus_id
    54 schema:value 21100466864
    55 rdf:type schema:PropertyValue
    56 Na37661fe16cf401686b82db277cdf9bb schema:name nlm_unique_id
    57 schema:value 101620585
    58 rdf:type schema:PropertyValue
    59 Na59f1608968948ed800295b96775c643 schema:author N6159a4958d00409494ebe4f342cc3653
    60 schema:ratingValue 2.798
    61 rdf:type schema:Rating
    62 Nc3a8c745133d47dd863e8b73a75ac2e4 schema:name wos_id
    63 schema:value 2051-1426/JOURNAL FOR IMMUNOTHERAPY OF CANCER
    64 rdf:type schema:PropertyValue
    65 Ne8ebae5a590d4bc0b3fcf141e7fabf0b rdf:first impact_factor_wos
    66 rdf:rest rdf:nil
    67 Nf055fbdbcbf74cd497adc7f8c110ea9c rdf:first snip
    68 rdf:rest rdf:nil
    69 Nf5ae42558ee944f4b59314a643d0bddb schema:author Ne8ebae5a590d4bc0b3fcf141e7fabf0b
    70 schema:dateCreated 2017
    71 schema:ratingValue 8.374
    72 rdf:type schema:Rating
    73 sg:ontologies/product-market-codes/B14000 schema:inDefinedTermSet sg:ontologies/product-market-codes/
    74 schema:name Immunology
    75 rdf:type schema:DefinedTerm
    76 sg:ontologies/product-market-codes/H33160 schema:inDefinedTermSet sg:ontologies/product-market-codes/
    77 schema:name Oncology
    78 rdf:type schema:DefinedTerm
     




    Preview window. Press ESC to close (or click here)


    ...